Ionis Pharmaceuticals, Inc.

NasdaqGS:IONS Lagerbericht

Marktkapitalisierung: US$11.9b

Ionis Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Die Gewinne von Ionis Pharmaceuticals sind mit einer durchschnittlichen Jahresrate von -4.4% zurückgegangen, während die Gewinne der Branche Biotechs um 29.1% pro Jahr wuchsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Jahresrate von 4.5%.

Wichtige Informationen

-4.44%

Wachstumsrate der Gewinne

-1.80%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie17.04%
Wachstumsrate der Einnahmen4.52%
Eigenkapitalrendite-77.98%
Netto-Marge-40.41%
Letzte Ertragsaktualisierung31 Mar 2026

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

IONS: Priority Review For Severe Triglycerides Will Reframe 2026 Risk Reward Profile

Analysts have raised their fair value estimate for Ionis Pharmaceuticals by about $3 to $96.73, citing updated assumptions for higher revenue growth, a wider profit margin, and a lower future P/E multiple, along with a series of recent price target increases and positive ratings resets from major firms. Analyst Commentary Recent research updates on Ionis Pharmaceuticals have leaned constructive, with several firms lifting price targets and reiterating positive ratings following the latest quarterly results and pipeline updates.

IONS: Priority FDA Reviews In 2026 Will Support Stronger Profitability Profile

Analysts have lifted the Ionis Pharmaceuticals fair value estimate by $3.24 to $120.00, as they factor in updated assumptions around revenue growth, profit margins, and future P/E multiples following recent price target increases across the Street. Analyst Commentary Bullish analysts have been lifting Ionis Pharmaceuticals price targets across several research updates, which feeds directly into the higher fair value estimate.

IONS: Priority Review For Severe Triglycerides Will Shape 2026 Outlook

Ionis Pharmaceuticals' updated analyst price target moves higher to $93.90 from $90.67. Analysts point to recent target hikes, Q4 results commentary and upcoming 2026 catalysts as key supports for this shift.

Ionis Pharmaceuticals' Peak Olezarsen Revenues Are Likely Very Conservative

Mar 20

IONS: 2026 Regulatory Event Risk Will Test Elevated Expectations

Ionis Pharmaceuticals' fair value estimate has been raised from $43.00 to about $62.78 as analysts factor in higher long term revenue growth assumptions, updated margin expectations, and recent price target increases following Q4 results, olezarsen progress, and a busy 2026 catalyst calendar. Analyst Commentary Recent Street research on Ionis Pharmaceuticals points to a more constructive stance on the story overall, but there are still threads of caution that matter if you are thinking about risk, valuation, and execution over the next couple of years.

IONS: Late-Stage RNA Programs Will Support Stronger Future Profitability Profile

Analysts have lifted their price target on Ionis Pharmaceuticals by $10, citing updated expectations around revenue growth, profit margins and a lower future P/E assumption, as reflected in recent research from firms covering the stock. Analyst Commentary Recent Street research points to a generally constructive tone on Ionis Pharmaceuticals, with bullish analysts highlighting both valuation and execution angles in their updated work.

IONS: Triglyceride Market Shift And SHTG Launch Progress Will Shape Outlook

Analysts nudged their fair value target for Ionis Pharmaceuticals slightly higher to about US$90.67 from roughly US$90.63, citing updated assumptions around discount rates, revenue growth, profit margins and a higher future P/E, along with recent Street research that highlights evolving expectations for the triglyceride lowering market where Ionis and Arrowhead both participate. Analyst Commentary Bullish Takeaways Bullish analysts view the refreshed fair value near US$90.67 as consistent with a company that could justify a higher future P/E, reflecting confidence in execution rather than only near term trading sentiment.

IONS: Upcoming SHTG Data And Launch Execution Will Support Bullish Thesis

Analysts have lifted their fair value estimate for Ionis Pharmaceuticals to about US$90.63 from roughly US$89.40, citing updated models that reflect recent Q3 performance, higher assumed revenue growth and profit margins, as well as a lower future P/E. This comes alongside Street price target increases to US$94 and US$99 following Tryngolza driven strength and expectations around upcoming SHTG data.

IONS: Late-Stage Data And New Launches Will Shape Balanced Risk Profile

Analysts nudged their fair value estimate for Ionis Pharmaceuticals higher from about $85.95 to roughly $89.40. They pointed to updated models that reflect recent price target increases, added expectations for Tryngolza in FCS and severe hypertriglyceridemia, and revised long term margin and P/E assumptions.

IONS: Late-Stage RNA Pipeline Will Drive Stronger Profitability Outlook

Analysts have raised their fair value estimate for Ionis Pharmaceuticals from approximately $96 to about $117 per share, citing strong Q3 outperformance led by Tryngolza, expanded peak sales assumptions for key lipid programs, and growing confidence in the late-stage pipeline and path to profitability. Analyst Commentary Bullish analysts are increasingly constructive on Ionis Pharmaceuticals following a series of positive catalysts, including strong Q3 performance from Tryngolza, encouraging late-stage data, and visible progress toward breakeven and long term profitability.

IONS: Late-Stage Data And Multiple Launches Will Shape Balanced Long-Term Outlook

Analysts have modestly raised their fair value estimate for Ionis Pharmaceuticals to approximately $86 per share. This reflects higher peak sales assumptions for Tryngolza and other late stage programs, a slightly richer pricing outlook in severe hypertriglyceridemia, and growing confidence in the company reaching multi billion dollar revenue and profitability in the early 2030s.

IONS: Upcoming Late-Stage Data and Recent Regulatory Progress Will Shape Balanced Outlook

Ionis Pharmaceuticals’ analyst price target has been raised from approximately $82 to $85 per share. This reflects analyst optimism following strong Phase 3 trial results, upward sales guidance, and an improved clinical and commercial outlook across multiple pipeline programs.

IONS: Continued Clinical Success Will Drive Meaningful Upside After Recent Regulatory Wins

The consensus analyst price target for Ionis Pharmaceuticals has increased significantly, rising from approximately $77 to over $82. Analysts cite robust clinical trial results, new product milestones, and a strengthened commercial outlook as key drivers behind their upward revisions.

Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91

Nov 01
Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91

Analyst Commentary Highlights Ionis Pharmaceuticals’ Upward Price Target and Valuation Amid Key Clinical Wins

Ionis Pharmaceuticals’ analyst price target has been raised from approximately $73 to $77. Analysts cite stronger-than-expected clinical and commercial progress across key late-stage programs, as well as expanded opportunities in rare disease markets.

Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach

Ionis Pharmaceuticals’ analyst price target has been raised from approximately $69.48 to $73.03, as analysts cite strong Phase 3 results across multiple programs and expanded opportunities in ultra-rare indications, which support increased sales and profit expectations. Analyst Commentary Recent analyst updates on Ionis Pharmaceuticals reveal a nuanced outlook as the company benefits from significant clinical milestones and expanding commercial prospects, but also faces some areas of uncertainty.

Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach

Analysts increased their price targets for Ionis Pharmaceuticals following "groundbreaking" Phase 3 data for olezarsen, blockbuster expectations, and a major regulatory win for Dawnzera, resulting in a modest consensus target rise from $68.35 to $69.48. Analyst Commentary Bullish analysts significantly raised price targets after Phase 3 trial data for olezarsen/Tryngolza in severe hypertriglyceridemia showed "groundbreaking" or "highly statistically significant" triglyceride reductions and, notably, the first proven benefit in reducing acute pancreatitis.

Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 34% Share Price Surge Not Quite Adding Up

Sep 03
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 34% Share Price Surge Not Quite Adding Up

Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach

Ionis Pharmaceuticals’ consensus price target edged up to $59.19 as analysts cited favorable FDA approval and label for Dawnzera in hereditary angioedema, strong initial launches, and growing pipeline confidence as key drivers, outweighing modest concerns on Wainua revenues. Analyst Commentary FDA approval of Dawnzera with a favorable, broad label (including both every four and eight week dosing) and absence of major safety warnings, positioning it competitively against Takhzyro and Andembry in hereditary angioedema.

Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS)

Aug 01
Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS)

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Too Much Debt?

Jul 30
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Too Much Debt?

Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up

Jul 03
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up

We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed

May 30
We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed

Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates

May 02
Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)

Apr 22
User avatar

Anticipated Drug Launches Will Shift Biotech Company To Commercial Stage

Ionis is set to boost revenue through first-mover advantage with TRYNGOLZA and other product launches targeting unmet medical needs.

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

Dec 23

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

Aufschlüsselung der Einnahmen und Ausgaben

Wie Ionis Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:IONS Einnahmen, Ausgaben und Erträge (USD Millions)
DatumEinnahmenGewinnAllgemeine und VerwaltungskostenF&E-Ausgaben
31 Dec 25944-3813940
30 Sep 25967-2563520
30 Jun 25944-2683170
31 Mar 25717-4582910
31 Dec 24705-4542670
30 Sep 24803-3592300
30 Jun 24813-3662390
31 Mar 24777-3852200
31 Dec 23788-3662330
30 Sep 23615-4092100
30 Jun 23631-3091740
31 Mar 23576-3291620
31 Dec 22587-2701500
30 Sep 2287571410
30 Jun 22849-281370
31 Mar 22841-41480
31 Dec 21810-291860
30 Sep 21661-6082070
30 Jun 21688-5502450
31 Mar 21708-4952720
31 Dec 20729-444354535
30 Sep 20933942990
30 Jun 209401452900
31 Mar 209591692930
31 Dec 191,1232812870
30 Sep 198214332690
30 Jun 197994022780
31 Mar 197523662690
31 Dec 186002772450
30 Sep 18575-412240
30 Jun 18548-381820
31 Mar 1854391380
31 Dec 17514191080
30 Sep 1750742810
30 Jun 1749952640
31 Mar 17426-15520
31 Dec 16373-60490
30 Sep 16238-184440
30 Jun 16176-227420
31 Mar 16258-134400
31 Dec 15284-88370
30 Sep 1531714310
30 Jun 1531223270

Qualität der Erträge: IONS ist derzeit unrentabel.

Wachsende Gewinnspanne: IONS ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: IONS ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 4.4% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von IONS verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: IONS ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (50.1%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: IONS hat eine negative Eigenkapitalrendite (-77.98%), da es derzeit unrentabel ist.

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/04/29 10:54
Aktienkurs zum Tagesende2026/04/29 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Ionis Pharmaceuticals, Inc. wird von 43 Analysten beobachtet. 22 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
James BirchenoughBarclays
Eliana MerleBarclays
Huidong WangBarclays